Published in Hepatology on October 01, 2000
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut (2006) 1.95
Preventing and treating hepatitis B infection. BMJ (2004) 1.80
Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol (2003) 1.43
Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol (2004) 1.24
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat (2006) 1.09
Management of hepatitis B in developing countries. World J Hepatol (2011) 1.08
Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother (2010) 0.99
Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep (2011) 0.99
Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol (2006) 0.98
Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver (2011) 0.97
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral hepatitis B. World J Gastroenterol (2002) 0.92
Future prospectives for the management of chronic hepatitis B. World J Gastroenterol (2007) 0.91
Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B. Mediterr J Hematol Infect Dis (2013) 0.90
Viral infection after renal transplantation: surveillance and management. Clin J Am Soc Nephrol (2008) 0.90
Prevalence and factors associated with hepatitis B virus infection among senior citizens in a southern brazilian city. Hepat Mon (2013) 0.87
Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. J Korean Med Sci (2010) 0.87
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol (2014) 0.83
Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B. Hepatol Int (2008) 0.82
Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J (2007) 0.82
A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: The 2-year results of a prospective study: Adefovir versus Entercavir for Chronic Hepatitis B. Hepat Mon (2011) 0.82
Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol (2005) 0.80
Pegylated IFN-alpha 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol (2006) 0.80
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. Clin Mol Hepatol (2015) 0.79
End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol (2004) 0.79
Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment. World J Gastroenterol (2006) 0.79
Safety and efficacy of oral HD-03/ES given for six months in patients with chronic hepatitis B virus infection. World J Gastroenterol (2007) 0.79
Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients. Comp Hepatol (2007) 0.78
Combination lamivudine and adefovir versus entecavir for the treatment of naïve chronic hepatitis B patients: a pilot study. Med Sci Monit (2013) 0.78
High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol (2006) 0.76
HBV and HCV therapy. Viruses (2009) 0.76
Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol (2014) 0.76
Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) (2012) 0.75
Why adefovir is not yet available in Canada. Can J Gastroenterol (2006) 0.75
Emerging drugs for hepatitis B. Expert Opin Emerg Drugs (2007) 0.75
Chronic hepatitis B: integrating long-term treatment data and strategies to improve outcomes in clinical practice. Gastroenterol Hepatol (N Y) (2011) 0.75
Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphism is Associated with Age Onset of Menarche in Sickle Cell Disease Females of India. Mediterr J Hematol Infect Dis (2013) 0.75
Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B. World J Gastroenterol (2007) 0.75
Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance. World J Gastroenterol (2010) 0.75
An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy (2006) 2.22
Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther (2005) 1.86
Early prediction of successful alpha-interferon therapy of chronic hepatitis C by core-IgM antibodies to hepatitis C virus. J Hepatol (1994) 1.40
Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? Aliment Pharmacol Ther (2014) 1.07
Desmoid tumor presenting as intra-abdominal abscess. Dig Dis Sci (2006) 1.04
Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis (2010) 1.03
High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant (2012) 1.02
Clinical predictors of poor outcomes among patients with nonvariceal upper gastrointestinal bleeding in Europe. Aliment Pharmacol Ther (2011) 1.01
Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study. Aliment Pharmacol Ther (2009) 0.99
Changing epidemiology and spreading modalities of hepatitis delta virus infection in Greece. Prog Clin Biol Res (1993) 0.99
Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat (2005) 0.98
Hepatitis E virus infection in a cohort of patients with acute non-A, non-B hepatitis. J Hepatol (1995) 0.98
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology (1997) 0.96
Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther (2008) 0.96
Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. J Viral Hepat (2010) 0.94
Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B virus infection in comparison to other markers of active virus replication. J Hepatol (1987) 0.93
Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy (2011) 0.92
Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol (1990) 0.92
Human immunodeficiency virus type 1 Tat-mediated trans activation correlates with the phosphorylation state of a cellular TAR RNA stem-binding factor. J Virol (1992) 0.90
Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment Pharmacol Ther (2007) 0.87
Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis (2007) 0.84
The role of the hepatitis delta virus in acute hepatitis and in chronic liver disease in Greece. Prog Clin Biol Res (1991) 0.84
Factors associated with severity and disease progression in chronic hepatitis C. Hepatogastroenterology (1999) 0.83
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther (2006) 0.83
Seasonal variation in exacerbations of ulcerative colitis. Hepatogastroenterology (1997) 0.83
Terbinafine-induced cholestatic liver disease. J Hepatol (1996) 0.83
The Bcl-2/Bax system and apoptosis in ulcerative colitis. Hepatogastroenterology (2007) 0.83
Histopathology of chronic hepatitis C in relation to epidemiological factors. J Hepatol (1996) 0.83
Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load. Vox Sang (2007) 0.82
Recurrent hepatitis C after liver transplantation. J Med Virol (2000) 0.81
Differential diagnosis of acute HBsAg positive hepatitis using IgM anti-HBc by a rapid, fully automated microparticle enzyme immunoassay. J Hepatol (1997) 0.81
Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Aliment Pharmacol Ther (2009) 0.80
Salvage procedures for trochanteric femoral fractures after internal fixation failure: biomechanical comparison of a plate fixator and the dynamic condylar screw. Proc Inst Mech Eng H (2011) 0.78
[Successful intrathecal treatment of meningeal leukaemia with methotrexate in the adult]. Dtsch Med Wochenschr (1973) 0.78
Predictors of the early development of advanced metachronous colon adenomas. Hepatogastroenterology (1997) 0.78
Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study. J Viral Hepat (2009) 0.78
p53 protein accumulation and colonic adenoma recurrence. Eur J Gastroenterol Hepatol (1999) 0.78
Effect of IgG and C-reactive protein on complement depletion by monosodium urate crystals. J Rheumatol (1983) 0.78
Failure after osteosynthesis of trochanteric fractures. Where is the limit of osteoporosis? Osteoporos Int (2013) 0.78
Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol (1996) 0.77
Endemic hepatitis delta virus infection in a Greek community. Prog Clin Biol Res (1987) 0.77
Intramedullary nailing of trochanteric fractures: central or caudal positioning of the load carrier? A biomechanical comparative study on cadaver bones. Injury (2013) 0.77
Yersinia enterocolitica endocarditis: case report and literature review. Eur J Clin Microbiol Infect Dis (1995) 0.77
Induction interferon therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther (2001) 0.77
Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial. Cancer Chemother Pharmacol (2006) 0.77
Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. Dig Liver Dis (2006) 0.76
Acute pancreatitis associated with Salmonella enteritidis. Am J Gastroenterol (2001) 0.76
Post-infantile giant cell hepatitis associated with autoimmune hepatitis and polyarteritis nodosa. Scand J Gastroenterol (2002) 0.76
Long-term outcome of chronic hepatitis C treated with interferon. Ital J Gastroenterol Hepatol (1999) 0.75
Sedation for upper gastrointestinal endoscopy: time for reappraisal? Gastrointest Endosc (1990) 0.75
Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther (2012) 0.75
Local hyperhidrosis. Dermatologica (1980) 0.75
Management of recurrent hepatitis C after liver transplantation. J Viral Hepat (2001) 0.75
Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. Eur J Gastroenterol Hepatol (1996) 0.75
Non-oxidative coupling of methane catalysed by supported tungsten hydride onto alumina and silica-alumina in classical and H2 permeable membrane fixed-bed reactors. Chem Commun (Camb) (2010) 0.75
Amineptine induced liver injury. Report of two cases and brief review of the literature. Hepatogastroenterology (1997) 0.75
Acute delta hepatitis in Greek parenteral drug abusers. Prog Clin Biol Res (1993) 0.75
Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease. J Hepatol (1994) 0.75
Prevalence of antibodies to hepatitis C virus in Greek patients with chronic liver disease. J Hepatol (1994) 0.75
Ventricular extrasystolic arrhythmias in exercise testing. II. Haemodynamic correlations. Eur Heart J (1987) 0.75
Indefinite dysplasia in ulcerative colitis has little clinical significance and is not associated with p53 protein accumulation. Am J Gastroenterol (1998) 0.75
HBeAg-negative hepatitis B in a previously thalassemic patient during immunosuppressive therapy for chronic GVHD. Bone Marrow Transplant (1998) 0.75
Comparative study of ceftriaxone versus cefamandole for pre-operative prophylaxis of infections in patients undergoing cesarean section or vaginal hysterectomy. J Chemother (1989) 0.75
Base changes at positions 1014 and 578 of delta virus RNA in Greek isolates maintain base pair in rod conformation with efficient RNA editing. J Med Virol (1995) 0.75
Hepatobiliary and pancreatic: spontaneous splenorenal shunts in portal hypertension. J Gastroenterol Hepatol (2006) 0.75